Supply of Roche Cardiac Marker Reagents (Troponin T, CK-MB, BNP)

The contract pertains to the supply of cardiac biomarker reagents, specifically including Troponin T, CK-MB, and BNP, which are essential for the diagnosis of myocardial infarction and other cardiac conditions. These reagents are manufactured by Roche and are intended for use in clinical laboratory settings to ensure accurate and timely detection of cardiac events. The agreement is structured as a subcontract under the Department of Veterans Affairs, managed by the 250-NETWORK Contract Office 10, and falls under the NAICS code 325414, which classifies it within the in vitro diagnostic substance manufacturing sector. The contract was posted on April 30, 2026, and while the place of performance and office address details are unspecified, the procurement is aimed at supporting diagnostic capabilities within VA healthcare facilities. There is no set-aside designation indicated, suggesting the opportunity is open to all qualified vendors without demographic or size-based preferences.